EC approves Amgen’s cholesterol-lowering medication Repatha
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
List view / Grid view
News
HerpV and GEN-003 will drive genital herpes treatment market growth to 2023
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
Phase I clinical trial of oral formulation of MGB-BP-3 for treatment of Clostridium Difficile infections begins
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
EC approves nivolumab for patients with previously-treated advanced squamous non-small cell lung cancer
21 July 2015 | By Victoria White
The EC has approved nivolumab for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy...
Researchers beat untreatable eczema with arthritis drug
20 July 2015 | By Victoria White
Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions...
Results of Phase 2 study of lonafarnib in HDV infected patients published
20 July 2015 | By Victoria White
Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published...
CheckMate -025, a Phase III Opdivo renal cell cancer trial, stopped early
20 July 2015 | By Victoria White
The CheckMate -025 study evaluating Opdivo versus everolimus in patients with advanced or metastatic RCC has been stopped early as it met its endpoint...
FDA orphan drug designation for C2N-8E12 for the treatment of progressive supranuclear palsy
20 July 2015 | By Victoria White
The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)...
UCLA Health victim of a criminal cyber attack
20 July 2015 | By Victoria White
UCLA Health was a victim of a criminal cyber attack and data on as many as 4.5 million individuals potentially may have been involved in the attack...
FDA approves Novo Nordisk’s FlexPro PenMate for people with growth hormone-related disorders
20 July 2015 | By Victoria White
The FDA has approved Novo Nordisk’s FlexPro PenMate, designed for users of Norditropin FlexPro pens who dislike needles and prefer them to be hidden...
Amgen announces positive blinatumomab Phase 2 study results in relapsed/refractory Ph+ B-Cell precursor ALL
20 July 2015 | By
Amgen has announced the top-line results of a Phase 2 trial evaluating blinatumomab in adults with relapsed or refractory Ph+ B-cell precursor ALL...
FDA QIDP designation for Motif’s iclaprim for HABP
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
GSK begins shipping 2015-16 US flu vaccines
17 July 2015 | By Victoria White
GSK has begun shipping Flaurix Quadrivalent (flu vaccine) doses to US healthcare providers and expects to begin shipping Flulaval Quadrivalent in August...
EC approves Evotaz for the treatment of HIV-1 infection in adults
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
